
Windtree Therapeutics Announces Positive Results in Heart Failure Study
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced encouraging topline results from its Phase 2b SEISMiC Extension Study investigating istaroxime in patients experiencing early cardiogenic shock due to heart …
Windtree Therapeutics Announces Positive Results in Heart Failure Study Read More